To Evaluate Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis Who Have Suboptimal Response to Ruxolitinib (LIMBER-304)
Summary
The lay summary the sponsor registered on ClinicalTrials.gov.
Investigators
The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.
- Albert Assad, M.D.
Incyte Corporation
Study Director
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
177 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Hanusch-Krankenhaus Wiener Gebietskrankenkasse
Vienna, Austria
- A.Z. St.-Jan A.V.
Bruges, Belgium
- Jessa Ziekenhuis
Hasselt, Belgium
- Az Delta
Roeselare, Belgium
- Chu Ucl Namur University Hospital Mont-Godinne
Yvoir, Belgium
- Peking University People'S Hospital (pkuph) - Institute of Hematology
Beijing, China
- Peking University Third Hospital
Beijing, China
- Peking University Third Hospital
Beijing, China
- Xuanwu Hospital Capital Medical University
Beijing, China
- the First Hospital of Jilin University
Changchun, China
- the First Peoples Hospital of Changzhou
Changzhou, China
- Fujian Medical University Union Hospital
Fuzhou, China
- Nanfang Hospital
Guangzhou, China
- the First Affiliated Hospital of Zhejiang University
Hangzhou, China
- Harbin Institute of Hematology and Oncology
Harbin, China
- University of Science and Technology of China-First Affiliated Hospital (anhui Provincial Hospital)
Hefei, China
- the Affiliated Hospital of Inner Mongolia Medical University
Hohhot, China
- Jinan Central Hospital
Jinan, China
- the Second Affiliated Hospital of Kunming Medical University
Kunming, China
- Lanzhou University Second Hospital
Lanzhou, China
- the First Hospital of Lanzhou University
Lanzhou, China
- Jiangxi Provincial of People Hospital
Nanchang, China
- the First Affiliated Hospital of Nanchang University
Nanchang, China
- Jiangsu Province Hospital
Nanjing, China
- the Affiliated Hospital of Qingdao University
Qingdao, China
- the First Hospital of China Medical University
Shenyang, China
- Shenzhen University Hospital
Shenzhen, China
- Institute of Hematology and Hospital of Blood Diseases, Chinese Academy of Medical Sciences and Pek
Tianjin, China
- Tianjin Medical University General Hospital
Tianjin, China
- Tongji Hospital Huazhong University of Science and Technology
Wuhan, China
- Union Hospital Affiliated To Tongji Medical College of Huazhong University of Science and Technology
Wuhan, China
- the Second Affiliated Hospital of Xi An Jiaotong University
Xi'an, China
- Yantai Yuhuangding Hospital
Yantai, China
- Henan Cancer Hostipal
Zhengzhou, China
- Henan Provincial Peoples Hospital
Zhengzhou, China
- Helsinki University Central Hospital
Helsinki, Finland
- Centre Hospitalier Universitaire Grenoble Alpes (chu Grenoble Alpes) - Hopital Albert Michallon
La Tronche, France
- Chu Limoges - Hopital Duputren
Limoges, France
- Chu de Limoges
Limoges, France
- Centre Hospitalier Universitaire de Nantes (chu de Nantes) - Hotel-Dieu
Nantes, France
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 26 May 2021
- Primary completion
- 16 Aug 2023
- Completion
- 21 Aug 2024
- Last update posted
- 2 Oct 2025
- Registered enrollment
- 177
- Registry id
- NCT04551053
Cross-registrations
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 4 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.